We found that PSMB8 or PSMB9 expression by tumor cells could be used as biomarkers in the clinic to predict TNBC prognosis, but whether both markers together would confer additional information or would be even more sensitive to predict outcomes remains to be determined. This evidence concerns the gene PSMB8 and neoplasm.